Merck & Co., Inc.·4

Feb 2, 4:05 PM ET

Zachary Jennifer 4

4 · Merck & Co., Inc. · Filed Feb 2, 2024

Insider Transaction Report

Form 4
Period: 2024-02-02
Zachary Jennifer
EVP, General Counsel
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-02$87.10/sh+19,417$1,691,22178,556.76 total
  • Sale

    Common Stock

    2024-02-02$126.97/sh49,499$6,284,77929,057.76 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-02-0219,41738,835 total
    Exercise: $87.10From: 2023-05-03Exp: 2032-05-02Common Stock (19,417 underlying)
Footnotes (3)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.8650 to $127.3000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]Holdings include shares acquired in dividend reinvestment transactions.
  • [F3]The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT